Literature DB >> 1826435

Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF.

C Tarella1, D Ferrero, M Bregni, S Siena, E Gallo, A Pileri, A M Gianni.   

Abstract

In 20 patients with non-Hodgkin lymphoma or breast cancer, high-dose cyclophosphamide induced, during the post-nadir period of rapid leucocyte recovery, on median day 19 about a 30-fold increase in the peak concentration of granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) colony-forming cells, and an even higher increase in the more immature pluripotent progenitors (CFU-Mix, 72-fold). After infusion of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), peak concentration was reached earlier (median day 15) and with further enhancements (159, 116 and 283-fold respectively, in the number of CFU-GM, BFU-E and CFU-Mix). Most CFU-GM were immature, lacking the differentiation antigen CD15, and gave rise to large myeloid colonies, reflecting a high proliferative capacity of the founder cells. Very immature maphosphamide-resistant progenitors were detectable. The marked expansion in the circulating pool was predictable and reliable, allowing harvesting, after two or three leukaphereses, of sufficient haematopoietic progenitors for autologous bone-marrow reconstitution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826435     DOI: 10.1016/0277-5379(91)90052-f

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

Review 1.  Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.

Authors:  K Leibundgut; A Hirt; A R Lüthy; A Tobler; H P Wagner
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 3.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

4.  Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation.

Authors:  Silvia Gaia; Antonella Olivero; Antonina Smedile; Marco Ruella; Maria Lorena Abate; Maurizio Fadda; Emanuela Rolle; Paola Omedè; Paola Bondesan; Roberto Passera; Alessandra Risso; Manuela Aragno; Alfredo Marzano; Alessia Ciancio; Mario Rizzetto; Corrado Tarella
Journal:  Hepatol Int       Date:  2013-10-11       Impact factor: 6.047

5.  IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P).

Authors:  F Hladik; K Kolbe; E U Irschick; M J Aman; G Gerken; L Färber; E Liehl; C Peschel; W E Aulitzky; C Huber
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

6.  Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood.

Authors:  E Shimizu; A Yamamoto; Y Takahashi; K Maniwa; S Yoshida; J Mukai; Y Takaue; T Ogura
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

7.  G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).

Authors:  Paolina Salamone; Giuseppe Fuda; Federico Casale; Giuseppe Marrali; Christian Lunetta; Claudia Caponnetto; Letizia Mazzini; Vincenzo La Bella; Jessica Mandrioli; Isabella Laura Simone; Cristina Moglia; Andrea Calvo; Corrado Tarella; Adriano Chio
Journal:  BMJ Open       Date:  2020-03-24       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.